Sorrento gets Brazilian ANVISA clearance to start Long COVID therapy trial

Sorrento Therapeutics has secured the Brazilian ANVISA authorisation to start a Phase IIa trial of COVI-MSC for treating long COVID.

Related Keywords

United Kingdom ,Brazil ,Brazilian ,Henry Ji ,Centric Services For ,Laboratory Equipment ,Synova Health ,Drug Processing Technology ,Sorrento Therapeutics ,Minute Walk Distance ,Clinical Trials Arena ,Processing Technology ,Centric Services ,Alternate Site Clinical Trials ,